Virginia Commonwealth University

Registry of the Natural History of Recurrent Pericarditis in Pediatric and Adult Patients

Status: Recruiting

Location: Alaska Heart & Vascular Institute, Allegheny General Hospital, Barnes-Jewish Hospital/Washington University, Cincinnati Children's Hospital Medical Center, Houston Methodist Hospital, Johns Hopkins University, Legacy Hospital and Health Center DBA Legacy Research Institute, Midwest Cardiovascular Research Foundation, NYU Langone Health, Northwell Health - Lenox Hill Hospital, Pima Heart and Vascular, Scripps Health, Seattle Children's Hospital, TKL Research Inc., University of California San Diego, University of Nebraska Medical Center, University of Vermont Medical Center, Virginia Commonwealth University

Conditions: Alaska Heart & Vascular Institute, Allegheny General Hospital, Barnes-Jewish Hospital/Washington University, Cincinnati Children's Hospital Medical Center, Houston Methodist Hospital, Johns Hopkins University, Legacy Hospital and Health Center DBA Legacy Research Institute, Midwest Cardiovascular Research Foundation, NYU Langone Health, Northwell Health - Lenox Hill Hospital, Pima Heart and Vascular, Scripps Health, Seattle Children's Hospital, TKL Research Inc., University of California San Diego, University of Nebraska Medical Center, University of Vermont Medical Center, Virginia Commonwealth University

City/State:

Anchorage, Alaska

Tucson, Arizona

La Jolla, California

San Diego, California

Davenport, Iowa

Baltimore, Maryland

Boston, Massachusetts

Minneapolis, Minnesota

Rochester, Minnesota

Saint Louis, Missouri

Omaha, Nebraska

Fair Lawn, New Jersey

New York, New York

New York, New York

Cincinnati, Ohio

Cleveland, Ohio

Portland, Oregon

Pittsburgh, Pennsylvania

Houston, Texas

Burlington, Vermont

Richmond, Virginia

Seattle, Washington

Contact Information:

Amanda Chriswell 907-550-2247 [email protected]

Aleksander Herber 520-576-4133 [email protected]

Study Coordinator 858-246-2413

Chelsea Butler 858-824-5241 [email protected]

Lori Christensen 563-324-2828 [email protected]

Kondal Reddy 410-502-2945 [email protected]

Wesley Xiong 617-732-4719 [email protected]

Stephanie Ebnet 612-863-3833

Halley Davidson 507-422-6246 [email protected]

Karen Bult 314-286-1767 [email protected]

Nathan Muhn 402-836-9364 [email protected]

Uzoma Okamgba-Nwoke 201-587-0500 ext 2548 [email protected]

Alexander Auchus 212-263-0855 [email protected]

212-434-4174 [email protected]

Mary Banks 513-636-2147 [email protected]

216-445-9007 [email protected]org

503-413-1612 [email protected]

Geetha Rayarao 412-359-4076

Eilidh Cowan 346-238-4552 [email protected]

Alexandria Loutrel 802-847-8913 [email protected]

Emily Federmann 804-828-2775 [email protected]

Nair Deepthi 206-987-1014 [email protected]

The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.

Read more

Effcacy and Safety of RPH-104 Treatment in Patients with Recurrent Pericarditis

Status: Not yet recruiting

Location: Virginia Commonwealth University

Conditions: Virginia Commonwealth University

City/State:

Richmond, Virginia

Contact Information:

Antonio Abbate, MD 804-828-0513 [email protected]

“The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis.
Pharmacokinetic and pharmacodynamic parameters of RPH-104 multiple doses in this patient population will be assessed as well.”

Read more

MYTHS – MYocarditis THerapy with Steroids

Status: Not yet recruiting

Location: University of California San Diego, Virginia Commonwealth University

Conditions: University of California San Diego, Virginia Commonwealth University

City/State:

San Diego, California

Richmond, Virginia

Contact Information:

Eric D Adler, MD

Antonio Abbate, MD

This is a phase III, multi-center international, single blind randomized controlled trial to test the efficacy of pulsed intravenous (IV) methylprednisolone versus standard therapy on top of maximal support in patients with Acute myocarditis (AM).

Read more

Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis

Status: Recruiting

Location: Massachusetts General Hospital, McGill University Health Care, MedStar Heart and Vascular Institute, Minneapolis Heart Institute Foundation, Palm Springs Community Health Centre, University of Alberta Hospital, University of Pennsylvania, University of Pittsburgh Medical Center, Virginia Commonwealth University

Conditions: Massachusetts General Hospital, McGill University Health Care, MedStar Heart and Vascular Institute, Minneapolis Heart Institute Foundation, Palm Springs Community Health Centre, University of Alberta Hospital, University of Pennsylvania, University of Pittsburgh Medical Center, Virginia Commonwealth University

City/State:

Washington, DC

Miami Lakes, Florida

Boston, Massachusetts

Minneapolis, Minnesota

Cleveland, Ohio

Malvern, Pennsylvania

Pittsburgh, Pennsylvania

Richmond, Virginia

Edmonton, Alberta, Canada

Montreal, Quebec, Canada

Contact Information:

Dr. Mark Hofmeyer [email protected]

Dr. Yanely Pineiro

Dr. Daniel Zlotoff [email protected]

Dr. David Lin [email protected]

Dr. Pavan Bhat [email protected]

Dr. Victor Ferrari [email protected]

Dr. Jessica Huston [email protected]

Dr. Roshanak Markley [email protected]

Dr. Justin Ezekowitz [email protected]

Dr. Matthias Friedrich [email protected]

“Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis within 90 days of onset of symptoms will be screened and, if eligible, randomized to CardiolRx or placebo.
CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC<5 ppm). The treatment period is 12 weeks; a last follow-up visit is scheduled one week after the last treatment, 13 weeks after randomization. Study assessments include Cardiac Magnetic Resonance imaging (CMR), ECG monitoring, 24-hour Holter assessments, the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as physical exams and laboratory tests. The primary outcome parameters are measured by CMR. Secondary outcomes include clinical endpoints and changes in inflammatory and biomarkers."

Read more
Click to access the login or register cheese
Contact Us

Contact Us

(281) 713-2962
800 Rockmead Drive, Suite 155
Kingwood, TX 77339
[email protected]

Social Media

Donations

Help Us End Suffering and Sudden Death from Myocarditis!

Donate to the Myocarditis Foundation Today!